je.st
news
Tag: presented
Sharon Schwartz presented Don L. Good Impact Award
2017-10-20 22:13:04| National Hog Farmer
Laughter and music filled the night air as Kansas State University Animal Sciences and Industry alumni and supporters gathered on Friday, October 13, at the Stanley Stout Center in Manhattan, Kansas. This evening marked the third annual ASI Family &a
Tags: good
don
presented
impact
SAES' Diver Detection Sonar being Presented at Monaco Yacht Show
2017-09-27 18:07:00| Naval Technology
SAES' diver detection sonar, DDS-03, is being presented at the Monaco Yacht Show, between 27-30 September.
Tags: show
presented
detection
monaco
Renewable Polyfarnesene Diol Technology Presented at CPIs Polyurethane Technical Conference
2017-09-20 14:00:00| Coatings World Breaking News
Tags: technology
technical
presented
conference
Interim Results from Phase 1b/2 Study Evaluating the Combination of Mercks KEYTRUDA (pembrolizumab) and Eisais HALAVEN (eribulin mesylate) Injection in Metastatic Triple-Negative Breast Cancer Presented at 2016 SABCS
2016-12-12 13:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. & WOODCLIFF LAKE, N.J. KENILWORTH, N.J. & WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Eisai Inc. today announced new interim data investigating Mercks anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in combination with Eisais microtubule dynamics inhibitor, HALAVEN (eribulin), in patients with metastatic triple-negative breast cancer (TNBC). Language: English Contact: Media:MerckPamela Eisele, 267-305-3558orKim Hamilton, (908) 740-1863orEisai Inc.Laurie Landau, 201-746-2510orInvestors:MerckTeri Loxam, 908-740-1986orAmy Klug, 908-740-1898orEisai Inc.Ivor Macleod, 201-746-2660 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
Tags: results
study
presented
combination
Updated KEYTRUDA (pembrolizumab) Data in Small Cell Lung Cancer and Mesothelioma Presented at 17th World Conference on Lung Cancer
2016-12-06 14:20:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Findings in Small Cell Lung Cancer and Malignant Pleural Mesothelioma Show Overall Response Rates of 33.3 Percent and 20.0 Percent, Respectively, in KEYNOTE-028 Long-Term Data Demonstrate Durable Responses in Difficult-to-Treat Cancers KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that updated findings from the phase 1b KEYNOTE-028 study investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in previously treated patients with advanced small cell lung cancer (SCLC) and malignant pleural mesothelioma, showed clinical activity and durable responses in some patients. Language: English Contact: Media:Pamela Eisele, 267-305-3558orCourtney Ronaldo, 908-236-1108orInvestorsTeri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] next »